Falkner, E. and Wild, C. (2008): Clinical application of Tissue Engineering: An overview of International and Austrian Areas of Research with a critical analysis of selected applications . LBI-HTA Projektbericht 013.

Gartlehner, G. (2007): [New vaccines: Horizon scanning]. HTA-Newsletter 59: p. 4.

Geiger-Gritsch, S. (2007): [Avastin® (Bevacizumab): Off-label use in cancer therapy]. HTA-Newsletter 58: p. 2.

Jonas, S. and Wild, C. and Schmetterer, L. and Sycha, T. and Frank, W. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections. Systematic review and meta-analysis]. ITA-Projektbericht 19.

Mathis, S. and Winkler, R. and Geiger-Gritsch, S. and Mittermayr, T. (2009): Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review. Decision Support Document 25.

Wild, C. (2005): [Immunoglobulin in neonates and preterm infants]. HTA-Newsletter 41: pp. 2-3.

Wild, C. (2005): . HTA-Newsletter 40: p. 4.

Wild, C. (2005): [Herceptin®/Trastuzumab for metastatic breast cancer]. HTA-Newsletter 40: p. 3.

Wild, C. (2005): [Targeted therapies]. ITA-Newsletter September 2005: pp. 11-12.

Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. HTA-Newsletter 40: p. 2.

Wild, C. (2005): [Erbitux®/Cetuximab for metastatic colorectal cancer]. HTA-Newsletter 40: pp. 2-3.

Wild, C. (2005): [Medical progress. Editorial]. HTA-Newsletter 40: pp. 1-2.

Wild, C. (2004): [Rituximab (MabThera®) as treatment for non-Hodgkin's lymphoma]. HTA-Newsletter 32: p. 3.

Wild, C. (2004): [LeukoScan®: Diagnostics of osteomyelitis]. HTA-Newsletter 26: pp. 2-3.

Wild, C. (2003): [Tumour vaccination]. HTA-Newsletter 19: p. 4.

Wild, C. (2002): [Trastuzumab for breast cancer]. HTA-Newsletter 12: p. 2.

Wild, C. (2002): [New drugs in the treatment of cancer. Editorial]. HTA-Newsletter 12: p. 1.

Wild, C. (2002): [Infliximab for Crohn's disease]. HTA-Newsletter 11: p. 4.

Wild, C. (2001): [Cytomegalovirus prophylaxis and therapy]. HTA-Newsletter 02: pp. 3-4.

Wild, C. and Jonas, S. (2001): [Immunoglobulins in transplant medicine: Prevention and therapy of cytomegalovirus infections]. ITA-Newsletter September 2001: pp. 9-10.

Wild, C. (2005): [Avastin®/Bevacizumab for metastatic colorectal cancer]. ÖKZ: Österreichische Krankenhauszeitung 46 (10): p. 51.

Wild, C. (2001): [Immunoglobulins: Effectiveness and costs]. ORF ON Science.

Wild, C. and Adlbrecht, C. (2007): [Avastin for age-related macular degeneration]. Rapid Assessment LBI-HTA 02.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2002): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. Transplantationsmedizin (02): pp. 65-73.

Wild, C. and Jonas, S. and Frank, W. and Schmetterer, L. and Sycha, T. (2001): [Immunoglobulins in transplant medicine. Prevention and therapy of cytomegalovirus infections: An Assessment]. European Surgery: Acta Chirurgica Austriaca 33 (Supplement 178).

Wild, C. and Piribauer, F. and Stergner, A. (2009): New influenza (swine flu) – data & facts for decision support. Decision Support Document 35.